Schrödinger (NASDAQ:SDGR) PT Lowered to $25.00 at BMO Capital Markets

Schrödinger (NASDAQ:SDGR) had its price target decreased by BMO Capital Markets from $30.00 to $25.00 in a report published on Thursday, Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley decreased their price target on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 21st. Leerink Partners began coverage on Schrödinger in a research note on Tuesday, July 2nd. They set an “outperform” rating and a $29.00 target price on the stock. Leerink Partnrs upgraded Schrödinger to a “strong-buy” rating in a research note on Tuesday, July 2nd. Finally, KeyCorp cut their price objective on shares of Schrödinger from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.60.

Schrödinger Stock Up 1.2 %

Shares of Schrödinger stock opened at $17.80 on Thursday. Schrödinger has a twelve month low of $16.67 and a twelve month high of $38.00. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -6.64 and a beta of 1.50. The company’s 50 day moving average is $19.31 and its 200 day moving average is $21.28.

Schrödinger (NASDAQ:SDGR) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.11. Schrödinger had a negative return on equity of 38.38% and a negative net margin of 100.42%. The firm had revenue of $47.33 million for the quarter, compared to the consensus estimate of $40.19 million. Sell-side analysts expect that Schrödinger will post -2.19 EPS for the current fiscal year.

Insider Activity

In related news, insider Margaret Dugan sold 1,531 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total value of $27,221.18. Following the sale, the insider now owns 13,469 shares in the company, valued at approximately $239,478.82. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Schrödinger

Large investors have recently modified their holdings of the stock. Texas Permanent School Fund Corp boosted its stake in Schrödinger by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 47,869 shares of the company’s stock worth $1,292,000 after buying an additional 626 shares during the period. Louisiana State Employees Retirement System lifted its holdings in Schrödinger by 2.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 27,800 shares of the company’s stock valued at $538,000 after buying an additional 700 shares in the last quarter. GAMMA Investing LLC boosted its position in Schrödinger by 49.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after buying an additional 703 shares during the period. ProShare Advisors LLC grew its stake in Schrödinger by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 10,987 shares of the company’s stock worth $297,000 after acquiring an additional 753 shares in the last quarter. Finally, Illinois Municipal Retirement Fund grew its stake in Schrödinger by 2.7% in the first quarter. Illinois Municipal Retirement Fund now owns 32,043 shares of the company’s stock worth $865,000 after purchasing an additional 831 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.